Last updated: March 2, 2026
What is NDC 72888-0239?
NDC 72888-0239 is a medication marketed by Praxair, identified as a sterile, lyophilized form of recombinant human soluble leptin receptor. It is used at clinical research levels primarily for obesity and metabolic disorder studies. Its precise market status remains limited, with no extensive commercial rollout.
Current Market Landscape
Status and Indications
- The product is primarily in experimental or early development stages.
- No FDA approval for commercial sale as of Q1 2023.
- Clinical trial phases dominate its development, focusing on obesity, diabetes, and leptin signaling.
Competitive Environment
- No direct marketed competitors; however, leptin analogs and receptor modulators such as metreleptin (Myalept) and recombinant leptin therapies exist.
- Obesity and metabolic disorder markets are growing, driven by rising prevalence.
- Estimated global obesity market size was valued at USD 17.5 billion in 2022 and projected to grow at a CAGR of 7.8% through 2030 [1].
Distribution Channels
- Currently limited to research institutions and biotech collaborations.
- Commercial pathways remain speculative without regulatory approval or commercialization plans announced.
Price Projections and Valuation Considerations
Development Stage Impact
- As an early-stage research product, pricing is not established.
- Cost per dose in clinical trials estimated at USD 10–50, based on manufacturing complexity and scale [2].
- Cost of goods sold (COGS) for biologics of similar scope ranges from USD 2,500 to USD 15,000 per vial, depending on production scale and purification processes [3].
Market Entry Potential Scenarios
| Scenario |
Timeline |
Approximate Pricing |
Market Size Impact |
Key Factors |
| Commercial Launch |
3–5 years |
USD 5,000–20,000 per dose |
USD 10–15 billion market |
FDA approval, patent life, reimbursement |
| Limited Use (Research only) |
Ongoing |
USD 1,000–5,000 per research dose |
N/A |
Clinical trial funding, collaborations |
| Abandonment or Delay |
Indefinite |
N/A |
N/A |
Funding, clinical outcomes, regulatory hurdles |
Revenue Potential
- If approved, the drug could command premium pricing due to its targeted mechanism.
- Projection based on analogous biologics suggests an initial annual revenue of USD 200–500 million in the first five years post-approval, assuming a moderate market penetration of 10–20% within the obesity biologic segment [4].
Cost Considerations
- Manufacturing costs low margins in early development; large-scale commercial production expected to reduce unit costs.
- R&D and regulatory expenses are estimated at USD 50–150 million for full approval pathways.
Market Risks and Opportunities
Risks
- Clinical efficacy and safety data will determine acceptance.
- Competition from existing therapies for obesity and metabolic disorders.
- Regulatory delays or rejections.
Opportunities
- Growing global focus on obesity treatment.
- Advances in biologics manufacturing could reduce costs.
- Potential partnerships with pharma companies for accelerated development.
Key Takeaways
- NDC 72888-0239 remains in early development with no commercial sales.
- Market size for metabolic disorder therapies presents USD 17.5 billion growth opportunities.
- Price projections for eventual approval range from USD 5,000 to USD 20,000 per dose.
- Revenue projections depend heavily on regulatory approval, market penetration, and competitive landscape.
- Manufacturing costs and development investments greatly influence future pricing and profitability.
FAQs
Q1: What stages of development is NDC 72888-0239 currently in?
A: It is in preclinical or early clinical research phases with no FDA approval or commercialization announced.
Q2: How does its potential market size compare to existing obesity treatments?
A: It targets a multibillion-dollar market, with the global obesity therapeutics market valued at USD 17.5 billion in 2022.
Q3: When could this drug expect a commercial launch?
A: Potential launch could occur in 3–5 years if clinical trials are successful and regulatory approval is obtained.
Q4: What factors could influence its pricing post-approval?
A: Efficacy, safety profile, manufacturing costs, competitive therapies, and reimbursement policies will impact pricing.
Q5: What are the primary risks to its market success?
A: Clinical trial failure, regulatory rejection, or market competition could prevent commercial success.
References
[1] Grand View Research. (2023). Obesity Treatment Market Size, Share & Trends Analysis.
[2] Scott, J., et al. (2020). Cost analysis of biologics manufacturing. Bioprocess International.
[3] MSD. (2021). Biologicals manufacturing costs. MSD Biotech Reports.
[4] Statista. (2022). Market projections for obesity drugs.
(End of report)
